West Pharma (NYSE: WST) reported Q2 EPS of $2.48, $0.27 better than the analyst estimate of $2.21. Revenue for the quarter came in at $771.3 million versus the consensus estimate of $755.08 million.

GUIDANCE:

West Pharma sees FY2022 EPS of $9.00-$9.12, versus the consensus of $9.32.

For earnings history and earnings-related data on West Pharma (WST) click here.